| Overview |
| bs-11662R |
| PADI2 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PADI2 |
| 42-120/665 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm |
| PAD 2; PAD H19; PAD-H19; PADI 2; Padi2; PADI2 protein; PADI2_HUMAN; PDI 2; PDI2 antibody Peptidlyarginine deiminase type II; Peptidyl arginine deiminase II; Peptidyl arginine deiminase type II; Peptidylarginine deiminase II; Protein arginine deiminase; Protein arginine deiminase type 2; Protein arginine deiminase type II; Protein-arginine deiminase type II; Protein-arginine deiminase type-2; KIAA0994; OTTHUMP00000044625. |
| The protein arginine deiminase (PAD) family of proteins, often referred to as peptidylarginine deiminases, catalyze the deimination of arginine residues of proteins. In the presence of calcium, the proteins in the PAD family act as catalysts for the posttranslational modification reaction that converts methylarginine to citrulline. The PAD proteins are cytoplasmic proteins primarily detected in eosinophils and neutrophils. The only tissue that contains all four forms of PAD (PADI1-4) is epidermis. PADI2 may play a crucial role during terminal differentiation of epidermal keratinocytes. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz